Keyphrases
COVID-19
100%
People Living with HIV (PLHIV)
67%
Antiretroviral Therapy
37%
Immunogenicity
30%
MRNA Vaccine
28%
SARS-CoV-2 Infection
28%
Vaccination
28%
HIV Patients
27%
Human Immunodeficiency Virus Type 1 (HIV-1)
26%
Vaccine Response
21%
Germinal Center
20%
Lymph Node
19%
Germinal Center B Cells
19%
Cell Response
17%
Interferon-α (IFN-α)
17%
B Cell Response
17%
Virus
17%
Infectious Diseases
16%
Natural Killer Cells
16%
Memory B Cells
16%
Chronic Inflammatory Diseases
16%
Monoclonal Antibody
16%
Placebo
15%
SARS-CoV-2 Vaccination
15%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
14%
Tolerability
14%
Influenza
14%
B Cells
14%
Germinal Center Reaction
14%
CD4+ T
14%
BNT162b2 Vaccine
13%
Tenofovir Disoproxil Fumarate
13%
Bone Marrow Plasma Cells
13%
Influenza Vaccination
13%
Omicron BA.1
12%
T Follicular Helper Cells
12%
Cytomegalovirus Infection
12%
Spike Protein
12%
CD4+ T Cells
12%
Neutralizing Antibodies
11%
Randomized Clinical Trial
11%
Omicron Variant
11%
Integrase Strand Transfer Inhibitor (INSTI)
11%
Tumor-draining Lymph Nodes
11%
Primary Antibody Deficiency
10%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
10%
Plasma Proteomics
10%
Phase II Trial
10%
Messenger RNA (mRNA)
10%
Inflammasome
10%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
97%
Spike
40%
B Cell
31%
COVID-19
30%
Human Immunodeficiency Virus
30%
Germinal Center
27%
Human Immunodeficiency Virus 1
26%
Omicron Coronavirus Variant
26%
Lymph Node
25%
Influenza
24%
Antibody Response
20%
Immunogenicity
20%
Natural Killer Cell
19%
Maturation
17%
Virus
16%
Memory B Cell
16%
Titer
16%
Cytotoxic T-Cell
16%
Neutralization
15%
Inflammatory Disorder
14%
T-Helper Cell
14%
Murine Cytomegalovirus
12%
CD4
12%
Macrophage
12%
Follicular B Helper T Cells
11%
Cytomegalovirus Infection
11%
Blood Plasma
11%
Monoclonal Antibody
11%
interferon
11%
Neutralizing Antibody
11%
Humoral Immune Deficiency
10%
Inflammasome
10%
Microbiome
9%
Intravenous Immunoglobulin
8%
Simian Immunodeficiency Virus
8%
Epitope
8%
Axillary Lymph Node
8%
Influenza Virus
7%
Probiotic
7%
Immunoglobulin Producing Cell
7%
CD4 Lymphocyte Count
7%
Influenza Vaccine
7%
Mediator
7%
Viral Disease
7%
Antibody Titer
6%
Immunosuppression
6%
Serum (Blood)
6%
Hepatitis Delta Virus
6%
Cytotoxicity
6%
Receptor Binding
6%
Medicine and Dentistry
Human Immunodeficiency Virus
85%
Severe Acute Respiratory Syndrome Coronavirus 2
49%
COVID-19
37%
Infection
33%
Placebo
21%
B Cell
18%
Antiretroviral Therapy
17%
Germinal Center
15%
Lymph Node
11%
Integrase
11%
Silo-Filler's Disease
10%
Virus
10%
Clinical Trial
8%
Adverse Event
8%
Interferon
8%
Memory B Cell
7%
Messenger RNA
7%
Cardiovascular Disease
7%
Diagnosis
6%
COVID-19 Vaccination
6%
Omicron Coronavirus Variant
6%
Antivirus Agent
6%
Arm
6%
Immunoglobulin Producing Cell
6%
Maturation
6%
Proteomics
6%
Pharmacokinetics
5%
Coronary Artery Calcium
5%
Hepatitis C
5%
Coronary Artery
5%
Complement Activation
5%
Asthma
5%
Immunogenicity
5%
Hematopoiesis
5%
Breathing
5%
Personalized Medicine
5%
Phase II Trials
5%
Cytokine Storm
5%
Socioeconomic Status
5%
Humoral Immune Deficiency
5%
Healthy Aging
5%
Chronic Hepatitis C
5%
Enzyme Linked Immunosorbent Assay
5%
Vascularity
5%
Human Immunodeficiency Virus 1 Infection
5%
Ritonavir
5%
Dolutegravir
5%
Osteolysis
5%
Atazanavir
5%
Diabetes Mellitus
5%